s condition meets withdrawal criteria.

2 trials

Sponsors

OncoTherapy Science, Inc., Wakayama Medical University

Conditions

Pancreatic cancer refractory to standard therapypancreatic cancer

Phase 3

A randomized, double-blind, placebo-controlled phase3 clinical trial of OCV-C01 for patients with pancreatic cancer refractory to standard therapy

Active, not recruitingJPRN-UMIN000007279

OncoTherapy Science, Inc.Pancreatic cancer refractory to standard therapy

Start: 2012-04-01Target: 300Updated: 2026-06-29

A double-blind, randomized clinical trial comparing S-1 in combination with DC vaccine loaded with WT1 peptides (TLP0-001) or placebo for the patients with advanced pancreatic cancer refractory to standard chemotherapy.

Active, not recruitingJPRN-UMIN000027179

Wakayama Medical Universitypancreatic cancer

Start: 2017-03-14Target: 185Updated: 2026-06-29

Related Papers

A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy

Trials2019-04-2726 citations